Preeclampsia Severe Clinical Trial
Official title:
Effect of Magnesium Sulphate on the Intracranial Pressure of Preeclamptic Patients Using Ultrasound Measured Optic Nerve Sheath Diameter: a Pilot Study
It had been shown that high percentage of severe preeclampsia patients got a high cerebral
perfusion pressure (CPP) due to abnormal autoregulation of cerebral blood vessels with
associated endothelial dysfunction and disrupted blood brain barrier. Moreover, patients with
high CPP is more likely to present with headache compared to other patients with normal
CPP.In this particular scenario, use of magnesium sulphate is associated with marked
reduction of CPP and. hence prevention of cerebral damage.This hypothesis was confirmed by
new magnetic resonance techniques that demonstrated brain edema in eclampsia/ severe
preeclampsia patient mostly due to vasogenic edema and less commonly attributed to cytotoxic
edema.
Changes in the optic nerve sheath diameter (ONSD) mirrors the changes in the Intracranial
pressure(ICP), subsequently when the intracranial pressure increases the optic nerve sheath
diameter (ONDS) also increases.
The aim of this study is to determine the effect Magnesium sulphate infusion on intracranial
pressure, in patients presented with severe preeclampsia by measuring changes in the ONSD
using ultrasound examination.
30 obstetric patients admitted to the HDU in Corniche Hospital for treatment of severe
preeclampsia. Patients with the following criteria will be excluded from the current work:
Patients undergone cranial or eye surgeries, Patients with known intracranial pathology,
Patients suffering from glaucoma or any other eye pathology that prevent clear identification
of the optic nerve, and Patients on drugs that may affect the cerebrospinal fluid [based on
operator decision].
In this prospective pilot study, patients who will fulfill the inclusion criteria will be
recruited at the time of admission in HDU by the investigators. The ONDS will be measured
before the commencement of Magnesium sulphate infusion, 1hr after finishing the loading dose,
6 and 24 hrs after infusion started. Patients will be in supine position with the head of the
bed less than 20 degrees. High frequency (7.5 MHz) linear probe will be used; it will be
placed gently over both closed eye after liberal application of sterile gel, the patient will
be instructed to look forward to align the optic nerve directly opposite to the probe. The
ONSD will be measured 3mm behind the optic disc in both the sagittal and transverse planes
and an average will be calculated and recorded. In the absence of complete visualization of
the optic disc, the largest viewed diameter will be taken as the maximal ONSD. Hemodynamic
variables & oxygen saturation will be recorded at the same times.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04243278 -
Postpartum Low-Dose Aspirin After Preeclampsia for Optimization of Cardiovascular Risk (PAPVASC)
|
Early Phase 1 | |
Not yet recruiting |
NCT03318211 -
Discontinuation of Magnesium Sulfate After Delivery in Women With Severe Preeclampsia. A Randomized Controlled Trial
|
Phase 4 | |
Completed |
NCT05594056 -
Transorbital Ultrasound of Optic Nerve Sheath Diameter Between Healthy Pregnant Women and Those With Severe Preeclampsia.
|
N/A | |
Recruiting |
NCT03761888 -
Nicardipine and Labetalol Effects on Cerebral Hemodynamics in Preeclampsia
|
||
Not yet recruiting |
NCT06373367 -
Preeclampsia Educational Program Study (PrEPS)
|
N/A | |
Not yet recruiting |
NCT04855513 -
Prevention of Pre-eclampsia Using Metformin: a Randomized Control Trial
|
N/A | |
Not yet recruiting |
NCT05232994 -
Metformin and Esomeprazole For Preterm Pre-eclampsia
|
Phase 1 | |
Completed |
NCT04392375 -
Nifedipine XL Versus Placebo for the Treatment of Preeclampsia With Severe Features During Induction of Labor
|
Phase 4 | |
Recruiting |
NCT03978767 -
Preeclampsia And Nonsteroidal Drugs for Analgesia: a Randomized Non Inferiority Trial
|
Phase 2 | |
Completed |
NCT04236258 -
Comparing Nifedipine and Enalapril in Medical Resources Used in the Postpartum Period
|
Phase 4 | |
Completed |
NCT04756661 -
Uterotonics for Severe Preeclampsia
|
N/A | |
Active, not recruiting |
NCT04660032 -
Nudge to Drive Transitions of Care
|
N/A | |
Completed |
NCT04103489 -
The Use of Eculizumab in HELLP Syndrome
|
Phase 1 | |
Enrolling by invitation |
NCT04794855 -
Risk Prediction Model of Preeclampsia
|
||
Recruiting |
NCT04311749 -
Expanded NIPT for Pregnancy Complications
|
||
Active, not recruiting |
NCT06359015 -
Metformin and Esomeprazole in Preterm Pre-eclampsia
|
Phase 4 | |
Recruiting |
NCT05610774 -
Optic Nerve Sheath Diameter in Pre-Eclamptic Parturient Receiving Magnesium Sulfate Combined With Dexmedetomidine
|
N/A | |
Completed |
NCT03815110 -
Preeclampsia Risk Assessment: Evaluation of Cut-offs to Improve Stratification
|
||
Completed |
NCT03451266 -
Effects of Vitamin C Administration on Extravascular Lung Water in Patients With Severe Features of Preeclampsia
|
Phase 1 | |
Active, not recruiting |
NCT06360601 -
Intravenous Labetalol Versus Hydralazine in Preeclampsia
|
Phase 1/Phase 2 |